We are live on ! Find out more
ONCY

Oncolytics Biotech
ONCY

33 hedge funds and large institutions have $1.38M invested in Oncolytics Biotech in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 4

0.37% more ownership

Funds ownership: 1.2% → 1.57% (+0.37%)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

4% less capital invested

Capital invested by funds: $1.43M → $1.38M (-$52.2K)

3% less funds holding

Funds holding: 34 → 33 (-1)

Holders
33
Holders Change
-1
Holders Change %
-2.94%
% of All Funds
0.53%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
12
Reduced
4
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Osaic Holdings
Osaic Holdings
Arizona
+$361K
2
Citadel Advisors
Citadel Advisors
Florida
+$79.4K
3
Renaissance Technologies
Renaissance Technologies
New York
+$27.1K
4
SS
Simplicity Solutions
Minnesota
+$18.2K
5
TRCT
Tower Research Capital (TRC)
New York
+$16.3K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$42K
2
LCM
Lynwood Capital Management
Ontario, Canada
-$41K
3
BAM
Brave Asset Management
New Jersey
-$32.8K
4
Stifel Financial
Stifel Financial
Missouri
-$25.9K
5
Rockefeller Capital Management
Rockefeller Capital Management
New York
-$9K

ONCY Hedge Fund Activity: Q1 2023 in Review

33 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q1 2023, worth a combined $1.38M — down 3.6% from $1.43M a quarter earlier.

Fund positioning in ONCY was balanced in Q1 2023: 6 funds opened new positions, 6 closed out, 12 added to existing stakes and 4 trimmed.

The largest buyer was Osaic Holdings, adding an estimated $361K. The largest seller was Millennium Management, exiting entirely with an estimated $42K sold.

  • 33 institutional investors held Oncolytics Biotech (ONCY) as of Q1 2023, down from 34 in Q4 2022.
  • Funds reported $1.38M of Oncolytics Biotech stock for Q1 2023, down 3.6% quarter-over-quarter.
  • 6 funds opened new Oncolytics Biotech positions in Q1 2023 and 6 closed out, a net change of 0 holders.
  • The largest Oncolytics Biotech buyer in Q1 2023 was Osaic Holdings, an estimated $361K added.
  • The largest Oncolytics Biotech seller in Q1 2023 was Millennium Management, an estimated $42K sold.

Based on aggregated 13F filings for Q1 2023.